⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 11, 2015Journal of Clinical OncologyOpen Access

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors

T. Khanh Deborah Wilsker Jiuping Ji Jennifer Zlott Tomoko Freshwater Robert J. Kinders Jerry M. Collins Alice P. Chen James H. Doroshow Shivaani Kummar

View Full Paper

Ask AI

Bookmark

Share

Abstract

This is the first report of AZD1775 single-agent activity in patients carrying BRCA mutations. Proof-of-mechanism was demonstrated by target modulation and DNA damage response in paired tumor biopsies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Khanh et al. (2015) studied this question.

synapsesocial.com/papers/69d7793f3fae90fd6048f3f1 https://doi.org/10.1200/jco.2014.60.4009

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonucleaseOriginal Research · 2011 · 197 citations
2Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide ConsumptionOriginal Research · 2012 · 307 citations
3MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracilEarly-Phase Clinical Trial · 2010 · 237 citations
4Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agentsOriginal Research · 2009 · 540 citations
5MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer XenograftsOriginal Research · 2011 · 274 citations

Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy2013
MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells2011
Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity2010
Methylphenidate for Hematologic Cancer–Related Fatigue: A Randomized Clinical TrialJournal of Clinical Oncology · 2026
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.4Journal of Clinical Oncology · 2026

More from Journal of Clinical Oncology

More from National Cancer Institute

More from Frederick National Laboratory for Cancer Research

More from Leidos (United States)